Overview

Effects of Dexmedetomidine on Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:
0

Participant gender:
All

Summary

Dexmedetomidine is a selective α2 adrenergic agonist that can be considered analgesics, anxiolytic,and anti-stress effect . This randomized, double-blind placebo-controlled trial of intraoperative dexmedetomidine for improvement of quality of recovery and analgesia from surgery. Patients scheduled to undergo video-assisted thoracoscopic surgery (VATS) will be enrolled. Patients will be recruited before the date of their surgery and will complete the Quality of Recovery-40 (QoR-40) questionnaire before their surgery and at 24 and 48 hours post op. They will also complete clinically significant pains score and oxygenation from the postanesthetic recovery unit (PACU).

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Yonsei University

Treatments:

Dexmedetomidine

Criteria

Inclusion Criteria:

1. The inclusion criteria included patients scheduled video-assisted thoracoscopic
surgery for lung cancer

2. Adults above 20 years of age and providing informed consent.

3. American Society of Anesthesiologists (ASA) Physical class II, & III patients

Exclusion Criteria:

1. severe functional liver or kidney disease

2. history of chronic pain requiring opioid treatment

3. arrhythmia or received treatment with antiarrythmic drug .

4. severe bradycardia (HR < 45 bpm) and AV block

5. pathologic esophageal lesion (esophageal stricture or varix )

6. pregnancy

7. psychiatric/central nervous system disturbance that would preclude completion of the
QoR-40 questionnaire

8. History of alcohol or drug abuse